Is Cosentyx Approved for Inflammatory Bowel Disease?
No, Cosentyx (secukinumab) is not approved by the FDA or EMA for treating inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. It targets IL-17A, a cytokine involved in psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.[1]
Why Might It Help IBD Despite No Approval?
IL-17A plays a role in IBD inflammation, and early research explored secukinumab for this. Two phase 2 trials tested it in Crohn's disease:
- A 2014 proof-of-concept study (78 patients) showed no significant endoscopic improvement over placebo; 4% response rate vs. 6% placebo.[2]
- A 2016 randomized trial (59 patients) found no clinical benefit; some patients worsened.[3]
These failures led Novartis to halt IBD development. Secukinumab can trigger or exacerbate IBD in some patients with related conditions like psoriasis—label warns of new-onset IBD cases.[1][4]
Related Uses in Gut Inflammation
Cosentyx treats axial spondyloarthritis, which often co-occurs with IBD (up to 10-20% of cases). It reduces spinal inflammation but does not address gut symptoms directly.[1] Hidradenitis suppurativa approval (2023) is skin-focused, unrelated to IBD.[5]
What IBD Treatments Work Instead?
Approved biologics include:
- Anti-TNFs: Infliximab (Remicade), adalimumab (Humira), certolizumab (Cimzia).
- Anti-integrins: Vedolizumab (Entyvio), gut-specific.
- Anti-IL-12/23: Ustekinumab (Stelara).
- Anti-IL-23: Risankizumab (Skyrizi) for Crohn's; mirikizumab (Omvoh) for ulcerative colitis.
| Drug | Target | Crohn's Approved? | UC Approved? |
|------|--------|-------------------|--------------|
| Infliximab | TNF | Yes | Yes |
| Vedolizumab | Integrin | Yes | Yes |
| Ustekinumab | IL-12/23 | Yes | Yes |
| Secukinumab | IL-17A | No | No |
Switching to IL-23 inhibitors (not IL-17) shows better IBD results.[6]
Risks of Off-Label Use for IBD
Prescribing Cosentyx off-label risks flares: post-marketing data report IBD onset or worsening in 0.1-0.5% of users.[4] No ongoing trials support it for IBD per ClinicalTrials.gov.[7]
Sources
[1]: FDA Cosentyx Label
[2]: NEJM 2014 Phase 2 Trial
[3]: Gastroenterology 2016
[4]: Novartis Safety Update
[5]: FDA Hidradenitis Approval
[6]: AGA Guidelines 2021
[7]: ClinicalTrials.gov Search